clemastine has been researched along with paclitaxel in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Freund, W; Hausamen, TU; Lipke, J; Löffler, TM | 1 |
| Diergarten, K; Goes-Schmieder, R; Kober, B; Kolotas, C; Martin, T; Mitrou, PS; Schneider, LV; Vogt, HG; Zamboglou, N | 1 |
| Heymanns, J; Köppler, H; Weide, R | 1 |
| Andersson, H; Boman, K; Parö, G; Puistola, U; Ridderheim, M; Rosenberg, P; Sorbe, B | 1 |
| den Bakker, MA; Gelderblom, H; Kloover, JS; van Meerbeeck, JP | 1 |
| Boere, IA; Bosch, TM; Cox, JM; Jager, A; Malmberg, R; Mathijssen, RHJ; Oomen-de Hoop, E; van den Bemt, PMLA; van Doorn, L; van Leeuwen, RWF | 1 |
1 review(s) available for clemastine and paclitaxel
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 trial(s) available for clemastine and paclitaxel
| Article | Year |
|---|---|
Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial.
Topics: Adult; Aged; Anti-Allergic Agents; Antiemetics; Antineoplastic Agents, Phytogenic; Cimetidine; Clemastine; Dexamethasone; Drug Administration Schedule; Female; Histamine H2 Antagonists; Humans; Infusions, Parenteral; Male; Middle Aged; Neoplasms; Ondansetron; Paclitaxel | 1996 |
Paclitaxel and simultaneous radiation in locally advanced stage IIIA/B non-small cell lung cancer: a clinical phase I study.
Topics: Adult; Aged; Anti-Allergic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clemastine; Combined Modality Therapy; Dexamethasone; Drug Administration Schedule; Drug Hypersensitivity; Drug Tolerance; Female; Histamine H2 Antagonists; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Premedication; Radiation-Sensitizing Agents; Radiotherapy Dosage; Ranitidine; Remission Induction; Treatment Outcome | 1996 |
Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions.
Topics: Adult; Aged; Aged, 80 and over; Anaphylaxis; Clemastine; Dexamethasone; Dose-Response Relationship, Drug; Drug Hypersensitivity; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Premedication; Ranitidine; Treatment Outcome | 2001 |
Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cimetidine; Clemastine; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug Hypersensitivity; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Injections, Intravenous; Life Tables; Middle Aged; Muscular Diseases; Nervous System Diseases; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Premedication; Salvage Therapy; Survival Analysis; Treatment Outcome | 2002 |
The added value of H
Topics: Adult; Aged; Aged, 80 and over; Chemoprevention; Clemastine; Dexamethasone; Drug Hypersensitivity; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Histamine H2 Antagonists; Humans; Infusions, Intravenous; Male; Medical Futility; Middle Aged; Neoplasms; Netherlands; Paclitaxel; Premedication; Ranitidine; Severity of Illness Index; Treatment Outcome | 2021 |
2 other study(ies) available for clemastine and paclitaxel
| Article | Year |
|---|---|
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clemastine; Dexamethasone; Drug Hypersensitivity; Fatal Outcome; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Ranitidine; Risk Factors | 2004 |